Schonfeld Strategic Advisors LLC
Position in KALV — KalVista Pharmaceuticals, Inc.
CIK 1665241
NEW YORK, NY
Position in KALV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,351,759
+$1,411,797 QoQ
Shares Held
315,537
+3.2% QoQ
Ownership
0.593%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#39
of 182 holders
Holding Since
Mar 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in KALV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Schonfeld Strategic Advisors LLC holds $296,187,490 across 126 Biotechnology names. KALV ranks #15 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | FOLD |
AMICUS THERAPEUTICS, INC.
|
1,757,899 | $25,419,219 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
71,767 | $23,745,547 | |
| 3 | PTCT |
Ptc Therapeutics, Inc.
|
318,405 | $21,692,932 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
324,722 | $18,882,584 | |
| 5 | INBX |
Inhibrx Biosciences, Inc.
|
254,827 | $17,132,019 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
62,142 | $11,747,945 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
494,737 | $10,364,740 | |
| 8 | INSM |
INSMED Inc
|
56,056 | $9,166,277 |
All Filings in KALV
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,351,759 | 315,537 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,939,962 | 305,880 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $5,436,810 | 446,372 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,642,413 | 145,282 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $6,713,348 | 581,746 | Shares | Sole | 2025-05-15 | |
| 2024-03-31 | $151,808 | 12,800 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||